Log in to search using one of your social media accounts:

 

Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Treatment-Free Remission in CML Sustainable After Nilotinib
Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks. (Source: CancerNetwork)
Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia & Lymphoma News Source Type: news

TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Cancer Drug That Might Slow Parkinson's, Alzheimer's Headed For Bigger Tests
In a preliminary study, the cancer drug nilotinib seemed to help patients with Parkinson's and dementia. Now two larger and more rigorous studies of the drug are under way.(Image credit: Zephyr/Science Source) (Source: NPR Health and Science)
Source: NPR Health and Science - March 15, 2017 Category: Consumer Health News Authors: Jon Hamilton Source Type: news

Tasigna Capsules (Nilotinib Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 6, 2017 Category: Drugs & Pharmacology Source Type: news

The Mast Cell: New Target in SpA? (CME/CE)
(MedPage Today) -- Nilotinib shows biomarker, clinical benefits in peripheral spondyloarthritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 12, 2016 Category: Primary Care Source Type: news

Nilotinib Shows Early Safety in Parkinson' Dementia Nilotinib Shows Early Safety in Parkinson' Dementia
Dr Alan Jacobs details a small proof-of-concept study, the first to treat persons with advanced Parkinson's with a tyrosine kinase inhibitor.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 25, 2016 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients
A propensity score –matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Leukemia drug shows early promise for treating Parkinson's disease and dementia
(IOS Press) Parkinson's disease is the second most common neurodegenerative disorder that causes a range of motor and non-motor symptoms. During the course of the disease, dopamine-producing neurons are lost and bundles of proteins known as Lewy bodies form in the brain. A study reported in the Journal of Parkinson's Disease provided molecular evidence that the FDA-approved leukemia drug nilotinib may restore brain dopamine and reduce toxic proteins associated with LB formation in PD and dementia patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2016 Category: Global & Universal Source Type: news

Frontline nilotinib supported for newly diagnosed CP–CML
Long-term results from the ENESTnd trial indicate a favourable risk–benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase–chronic myeloid leukaemia diagnosis. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news

Cancer Drug Shows Promise in Parkinson's Dementia Cancer Drug Shows Promise in Parkinson's Dementia
Low-dose nilotinib improved biomarkers, cognition, and motor skills in a small phase 1 study of patients with Parkinson's dementia and Lewy body dementia. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 21, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Parkinson's victims 'brought back to life' by cancer drug nilotinib
Researchers in Washington now hope the 'life-changing' drug - a leukaemia treatment called nilotinib - will also work for those with brain conditions such as Alzheimer's. (Source: the Mail online | Health)
Source: the Mail online | Health - October 19, 2015 Category: Consumer Health News Source Type: news

Man walks again as cancer drug is trialled for Parkinson's
Nilotinib, a drug used to treat leukemia, has been trialled with success on a small group with Parkinson's and Lewy body dementia, improving cognitive ability and biomarkers (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - October 19, 2015 Category: Neurology Tags: Parkinson's Disease Source Type: news

Medical News Today: Man walks again as cancer drug is trialled for Parkinson's
Nilotinib, a drug used to treat leukemia, has been trialled with success on a small group with Parkinson's and Lewy body dementia, improving cognitive ability and biomarkers (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 19, 2015 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news

Cancer drug improved cognition, motor skills in small Parkinson's clinical trial
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson's disease and Lewy body dementia in a small phase I clinical trial, report researchers. In addition, the drug, nilotinib (Tasigna by Novartis), led to statistically significant and encouraging changes in toxic proteins linked to disease progression (biomarkers). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 17, 2015 Category: Science Source Type: news

Tasigna Shows Promise in Systemic Sclerosis (CME/CE)
(MedPage Today) -- Skin scores improved at 12 months, but tolerability limited by mild QTc prolongation (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 27, 2015 Category: Dermatology Source Type: news

Laurie Letvak
Vice President and Head of Clinical Development Policy Dr. Laurie Letvak is Vice President and Head of Clinical Development Policy at Novartis, a position she has held since June 2014. Laurie has been with Novartis for 20 years in a variety of positions.  She played a key role in the development of Gleevec® since joining the International Project Team in 2001, responsible for Global Medical Affairs.   She led the development of the Medical Affairs program, which resulted in many key studies, some of which have provided the data for new indications for Gleevec ®, including Ph+ ALL and Adjuvant GIST.&n...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news

87% Complete Remission Rate With Nilotinib in ALL87% Complete Remission Rate With Nilotinib in ALL
Low-intensity chemotherapy plus nilotinib was highly effective in older patients, and might be an alternative to stem cell transplantation. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novartis Japan Apologizes Again for Second Side-Effects Scandal
The Japanese unit of Novartis has apologized for failing to report the side-effects of its leukemia drugs, Gleevec and Tasigna -- the second recent scandal the drugmaker has faced surrounding inappropriately-reported side-effects. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2014 Category: Pharmaceuticals Source Type: news

Nilotinib Associated With Increased Peripheral Artery Disease Rate in CML
Two studies found higher rates of peripheral artery occlusive disease in nilotinib-treated chronic myeloid leukemia patients than in imatinib-treated patients. (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news

Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib
CML patients treated with nilotinib had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease. (Source: Cancer Network)
Source: Cancer Network - April 12, 2013 Category: Cancer & Oncology Source Type: news

CHMP recommends approval of bosutinib (Bosulif®) for CML
Source: European Medicines Agency Area: News The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a conditional marketing authorisation for the orphan medicine bosutinib (Bosulif®) for the treatment of adults with Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. Bosutinib is a protein kinase inhibitor that acts by inhibiting the abnormal Bcr-Abl kinase that promotes CML.   The posit...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news

Early molecular response may predict outcomes for nilotinib in CML
Branford S. J Clin Oncol. 2012;doi:10.1200/JCO.2011.40.5217. (Source: HemOncToday.com)
Source: HemOncToday.com - January 14, 2013 Category: Cancer & Oncology Source Type: news